Table 5.

Description of MACE depending on prior antithrombotic therapy

						Study population n = 72
MACE	No AT n = 3	AT n = 28	Dual AT n = 29	OAC n = 6	AT + OAC n = 4	Triple therapy n = 2
No event	2 (3%)	25 (35%)	25 (35%)	5 (7%)	4 (6%)	2 (3%)
With Event	1 (1%)	3 (4%)	4 (6%)	1 (1%)	0	0
Myocardial infarction	0	1 (1%)	0	0	0	0
Stroke	0	1 (1%)	1 (1%)	1 (1%)	0	0
Recurrence of TTS	0	0	1 (1%)	0	0	0
Death	1 (1%)	1 (1%)	2 (3%)	0	0	0

Data is presented as number of patients and percentage

MACE major adverse cardiac event, AT antiplatelet therapy, OAC anticoagulation therapy